Company: TDBCP
Filing Date: 2025-06-30
Form Type: 424B2
Source: 0001140361-25-024183
Chunk: 10

Company: TORONTO DOMINION BANK
Filing Date: 2025-06-30
Form: 424B2
Chunk 10
---
 notes in the secondary market, you should consult your tax advisors as to the consequences of acquiring, holding and disposing of the notes and receiving the payments that might be 
 due under the notes.                                                                                                                                                                                                                            |

Additional Risk Factors The stocks held by the Underlying Fund are concentrated in one sector. The Underlying Fund holds securities issued by companies in the biotechnology sector. As a result, the stocks that will determine the performance of the Underlying Fund are concentrated in one sector. Although an investment in the notes will not give holders any ownership or other direct interests in the securities held by the Underlying Fund, the return on an investment in the notes will be subject to certain risks associated with a direct equity investment in companies in the biotechnology sector. Accordingly, by investing in the notes, you will not receive the full benefit from the diversification which could result from an investment linked to companies that operate in multiple sectors. Adverse conditions in the biotechnology sector may reduce your return on the notes.

| Accelerated Return Notes® | TS-7 |

All of the stocks held by the Underlying Fund are issued by companies whose primary lines of business are directly associated with the biotechnology sector. The profitability of these companies is largely dependent on, among other things, demand for the companies’ products, regulatory influences on the biotechnology market (including healthcare reform and receipt of regulatory approvals and compliance with complex regulatory requirements), pricing and reimbursement from third party payors, continued innovation and successful development of new products, talent attraction and retention, maintaining intellectual property rights and industry competition. Any adverse developments affecting the biotechnology sector could adversely affect the price of the Underlying Fund and, in turn, the value of the notes. The sponsor or investment advisor of the Underlying Fund may adjust the Underlying Fund in a way that affects its prices, and the sponsor or investment advisor has no obligation to consider your interests. The sponsor or investment advisor of the Underlying Fund can add, delete, or substitute the components included in the Underlying Fund or make other methodological changes that could change its price. Any of these actions could adversely affect the value of your notes.

| Accelerated Return Notes® | TS-8 |

The Underlying Fund All disclosures contained in this term sheet regarding the Underlying Fund, including, without limitation, its make-up, method of calculation, and changes in its components, have been derived from publicly available sources. The information reflects the policies of, and is subject to change by, SSGA Funds Management, Inc., the advisor to the Under